Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndromeMaria Antonietta Aloe Spiriti, Maria Concetta Petti, Roberto Latagliata et al.|Annals of Hematology|2004Cited by 110
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label studyPaola Tacchetti, Gianpietro Semenzato, Mónica Galli et al.|The Lancet Haematology|2020Cited by 58
Bortezomib-Thalidomide-Dexamethasone Incorporated Into Autotransplantation Is Associated with More Favorable Outcomes After Relapse in Comparison with Thalidomide-Dexamethasone Plus Autotransplantation in Multiple MyelomaMichèle Cavo, Mario Boccadoro, Mónica Galli et al.|Blood|2012Cited by 3